Glucocorticoids such as dexamethasone will affect NEP and NK-1R antagonists will block the NK-1R in treatment strategy, as was shown in a previous clinical trial in patients with COVID-19 (2, 3). The gene discussed is TACR1; the disease is COVID-19.